Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02SKQ
|
|||
| Drug Name |
PMID29334795-Compound-28
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Histamine H3-associated disorder [ICD-11: NE61] | Patented | [1] | |
| Company |
ARENA PHARMACEUTICALS, INC
|
|||
| Structure |
 |
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | . | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.